Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bcp.12987 http://scihub22266oqcxt.onion/10.1111/bcp.12987 C5338117!5338117 !27111518     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27111518 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27111518 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Br+J+Clin+Pharmacol 2016 ; 82 (3 ): 659-72 Nephropedia Template TP {{tp|p=27111518 |t=2016. Therapeutic nucleic acids: current clinical status |pdf=|usr=}}{{27111518 }} gab.com Text Therapeutic nucleic acids: current clinical status JO: Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=27111518 #FOAvip Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) are simple linear polymers that have been the subject of considerable research in the last two decades and have now moved into the realm of being stand-alone therapeutic agents. Much of this has stemmed from the appreciation that they carry out myriad functions that go beyond mere storage of genetic information and protein synthesis. Therapy with nucleic acids either uses unmodified DNA or RNA or closely related compounds. From both a development and regulatory perspective, they fall somewhere between small molecules and biologics. Several of these compounds are in clinical development and many have received regulatory approval for human use. This review addresses therapeutic uses of DNA based on antisense oligonucleotides, DNA aptamers and gene therapy; and therapeutic uses of RNA including micro RNAs, short interfering RNAs, ribozymes, RNA decoys and circular RNAs. With their specificity, functional diversity and limited toxicity, therapeutic nucleic acids hold enormous promise. However, challenges that need to be addressed include targeted delivery, mass production at low cost, sustaining efficacy and minimizing off-target toxicity. Technological developments will hold the key to this and help accelerate drug approvals in the years to come. Twit Text FOAVip Therapeutic nucleic acids: current clinical status ????Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=27111518 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27111518 #FOAvip English Wikipedia <ref>{{Cite pmid|27111518 }}</ref> Therapeutic nucleic acids: current clinical status #MMPMID27111518 Sridharan K ; Gogtay NJ Br J Clin Pharmacol 2016[Sep]; 82 (3 ): 659-72 PMID27111518 show ga Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) are simple linear polymers that have been the subject of considerable research in the last two decades and have now moved into the realm of being stand-alone therapeutic agents. Much of this has stemmed from the appreciation that they carry out myriad functions that go beyond mere storage of genetic information and protein synthesis. Therapy with nucleic acids either uses unmodified DNA or RNA or closely related compounds. From both a development and regulatory perspective, they fall somewhere between small molecules and biologics. Several of these compounds are in clinical development and many have received regulatory approval for human use. This review addresses therapeutic uses of DNA based on antisense oligonucleotides, DNA aptamers and gene therapy; and therapeutic uses of RNA including micro RNAs, short interfering RNAs, ribozymes, RNA decoys and circular RNAs. With their specificity, functional diversity and limited toxicity, therapeutic nucleic acids hold enormous promise. However, challenges that need to be addressed include targeted delivery, mass production at low cost, sustaining efficacy and minimizing off-target toxicity. Technological developments will hold the key to this and help accelerate drug approvals in the years to come. |Aptamers, Nucleotide/therapeutic use [MESH] |DNA/*therapeutic use [MESH] |Genetic Therapy/methods [MESH] |Humans [MESH] |MicroRNAs/therapeutic use [MESH] |Oligonucleotides, Antisense/therapeutic use [MESH] |RNA, Catalytic/therapeutic use [MESH] |RNA, Small Interfering/therapeutic use [MESH]Therapeutic nucleic acids: current clinical status (epmc).pdf DeepDyve Pubget Overpricing